These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 32555626

  • 1. miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma.
    Grzywa TM, Klicka K, Paskal W, Dudkiewicz J, Wejman J, Pyzlak M, Włodarski PK.
    PLoS One; 2020; 15(6):e0234707. PubMed ID: 32555626
    [Abstract] [Full Text] [Related]

  • 2. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
    Wang X, Qu H, Dong Y, Wang G, Zhen Y, Zhang L.
    Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
    [Abstract] [Full Text] [Related]

  • 3. miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma.
    Díaz-Martínez M, Benito-Jardón L, Alonso L, Koetz-Ploch L, Hernando E, Teixidó J.
    Cancer Res; 2018 Feb 15; 78(4):1017-1030. PubMed ID: 29229605
    [Abstract] [Full Text] [Related]

  • 4. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
    Kim JH, Ahn JH, Lee M.
    Cancer Res Treat; 2017 Oct 15; 49(4):947-959. PubMed ID: 28052651
    [Abstract] [Full Text] [Related]

  • 5. MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAFV600E-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance.
    Lee B, Sahoo A, Sawada J, Marchica J, Sahoo S, Layng FIAL, Finlay D, Mazar J, Joshi P, Komatsu M, Vuori K, de Jong PR, Ray A, Perera RJ.
    J Invest Dermatol; 2021 Feb 15; 141(2):385-394. PubMed ID: 32888955
    [Abstract] [Full Text] [Related]

  • 6. Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway.
    Gad SA, Ali HEA, Gaballa R, Abdelsalam RM, Zerfaoui M, Ali HI, Salama SH, Kenawy SA, Kandil E, Abd Elmageed ZY.
    Sci Rep; 2019 Oct 02; 9(1):14197. PubMed ID: 31578454
    [Abstract] [Full Text] [Related]

  • 7. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.
    Li K, Tang M, Tong S, Wang C, Sun Q, Lv M, Sun X, Wang T, Jin S.
    Apoptosis; 2020 Apr 02; 25(3-4):179-191. PubMed ID: 32056038
    [Abstract] [Full Text] [Related]

  • 8. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.
    Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Drießen S, Stork B, Wesselborg S, Schaller M, Biedermann T, Bauer J, Lasithiotakis K, Weide B, Eberle J, Schittek B, Schadendorf D, Garbe C, Kulms D, Meier F.
    Sci Signal; 2013 Jan 29; 6(260):ra7. PubMed ID: 23362240
    [Abstract] [Full Text] [Related]

  • 9. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
    Sun X, Li J, Sun Y, Zhang Y, Dong L, Shen C, Yang L, Yang M, Li Y, Shen G, Tu Y, Tao J.
    Oncotarget; 2016 Aug 16; 7(33):53558-53570. PubMed ID: 27448964
    [Abstract] [Full Text] [Related]

  • 10. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
    Hartman ML, Sztiller-Sikorska M, Gajos-Michniewicz A, Czyz M.
    Cells; 2020 Jan 07; 9(1):. PubMed ID: 31936151
    [Abstract] [Full Text] [Related]

  • 11. BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells.
    Lunavat TR, Cheng L, Einarsdottir BO, Olofsson Bagge R, Veppil Muralidharan S, Sharples RA, Lässer C, Gho YS, Hill AF, Nilsson JA, Lötvall J.
    Proc Natl Acad Sci U S A; 2017 Jul 18; 114(29):E5930-E5939. PubMed ID: 28684402
    [Abstract] [Full Text] [Related]

  • 12. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
    Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C, Amaravadi RK.
    J Clin Invest; 2014 Mar 18; 124(3):1406-17. PubMed ID: 24569374
    [Abstract] [Full Text] [Related]

  • 13. ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.
    Peng U, Wang Z, Pei S, Ou Y, Hu P, Liu W, Song J.
    Oncol Rep; 2017 Feb 18; 37(2):1270-1276. PubMed ID: 28035401
    [Abstract] [Full Text] [Related]

  • 14. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
    Caporali S, Amaro A, Levati L, Alvino E, Lacal PM, Mastroeni S, Ruffini F, Bonmassar L, Antonini Cappellini GC, Felli N, Carè A, Pfeffer U, D'Atri S.
    J Exp Clin Cancer Res; 2019 Jun 21; 38(1):272. PubMed ID: 31227006
    [Abstract] [Full Text] [Related]

  • 15. miR-579-3p controls melanoma progression and resistance to target therapy.
    Fattore L, Mancini R, Acunzo M, Romano G, Laganà A, Pisanu ME, Malpicci D, Madonna G, Mallardo D, Capone M, Fulciniti F, Mazzucchelli L, Botti G, Croce CM, Ascierto PA, Ciliberto G.
    Proc Natl Acad Sci U S A; 2016 Aug 23; 113(34):E5005-13. PubMed ID: 27503895
    [Abstract] [Full Text] [Related]

  • 16. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
    Atzori MG, Ceci C, Ruffini F, Trapani M, Barbaccia ML, Tentori L, D'Atri S, Lacal PM, Graziani G.
    J Cell Mol Med; 2020 Jan 23; 24(1):465-475. PubMed ID: 31758648
    [Abstract] [Full Text] [Related]

  • 17. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.
    Ma ZR, Xiong QW, Cai SZ, Ding LT, Yin CH, Xia HL, Liu W, Dai S, Zhang Y, Zhu ZH, Huang ZJ, Wang Q, Yan XM.
    Int Immunopharmacol; 2023 Sep 23; 122():110617. PubMed ID: 37478666
    [Abstract] [Full Text] [Related]

  • 18. miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma.
    Nguyen MT, Lin CH, Liu SM, Miyashita A, Ihn H, Lin H, Ng CH, Tsai JC, Chen MH, Tsai MS, Lin IY, Liu SC, Li LY, Fukushima S, Lu J, Ma N.
    Neoplasia; 2020 Dec 23; 22(12):789-799. PubMed ID: 33142243
    [Abstract] [Full Text] [Related]

  • 19. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model.
    Jandova J, Wondrak GT.
    J Invest Dermatol; 2022 May 23; 142(5):1456-1465.e1. PubMed ID: 34687745
    [Abstract] [Full Text] [Related]

  • 20. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
    Hao J, Fan W, Li Y, Tang R, Tian C, Yang Q, Zhu T, Diao C, Hu S, Chen M, Guo P, Long Q, Zhang C, Qin G, Yu W, Chen M, Li L, Qin L, Wang J, Zhang X, Ren Y, Zhou P, Zou L, Jiang K, Guo W, Deng W.
    J Exp Clin Cancer Res; 2019 Feb 04; 38(1):48. PubMed ID: 30717768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.